Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-0459PMID 17108129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• / rGel 121 by the Vascular Targeting Agent VEGF Inhibition of Prostate Tumor Growth and Bone Remodeling

  2006cited by this paper
• VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice.

  2005cited by this paper
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

  2005cited by this paper
• Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective.

  2005cited by this paper
• The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

  2005cited by this paper
• Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.

  2005cited by this paper
• Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

  2005cited by this paper
• Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.

  2004cited by this paper
• VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.

  2004cited by this paper
• Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

  2004cited by this paper
• Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer.

  2004cited by this paper
• Inhibitory Deficits, Delay Aversion and Preschool AD/HD: Implications for the Dual Pathway Model

  2004cited by this paper
• Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer

  2004cited by this paper
• Metastatic Properties of Prostate Cancer Cells are Controlled by VEGF

  2004cited by this paper
• Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein

  2004cited by this paper
• Effect of antisense VEGF cDNA transfection on the growth of chronic myeloid leukemia K562 cells in vitro and in nude mice.

  2004cited by this paper
• Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.

  2003cited by this paper
• The Role of RANKL (TRANCE/TNFSF11), a Tumor Necrosis Factor Family Member, in Skeletal Development: Effects of Gene Knockout and Transgenic Rescue

  2003cited by this paper
• Transforming growth factor-beta in osteolytic breast cancer bone metastases.

  2003cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation.

  2003cited by this paper
• RANKL and Vascular Endothelial Growth Factor (VEGF) Induce Osteoclast Chemotaxis through an ERK1/2-dependent Mechanism*

  2003cited by this paper
• Possible Involvement of the Vascular Endothelial Growth Factor-Flt-1-Focal Adhesion Kinase Pathway in Chemotaxis and the Cell Proliferation of Osteoclast Precursor Cells in Arthritic Joints1

  2002cited by this paper
• In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

  2002cited by this paper
• Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.

  2002cited by this paper
• Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

  2002cited by this paper
• Prefrontal cortex: One step at a time?

  2002cited by this paper
• Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis.

  2002cited by this paper
• Biology of osteoclast activation in cancer.

  2001cited by this paper
• Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)

  2001cited by this paper
• VEGF Receptor Signal Transduction

  2001cited by this paper
• Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

  2001cited by this paper
• Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state.

  2000cited by this paper
• Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation.

  2000cited by this paper
• Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones

  2000cited by this paper
• Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

  2000cited by this paper
• VEGF receptor signaling in tumor angiogenesis.

  2000cited by this paper
• Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

  1999cited by this paper
• The genetic transformation of bone biology.

  1999cited by this paper
• Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.

  1999cited by this paper
• Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.

  1999cited by this paper
• Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption

  1999cited by this paper
• VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

  1999cited by this paper
• VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

  1999influential reference
• Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone

  1998cited by this paper
• DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma

  1998cited by this paper
• Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.

  1998cited by this paper
• Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

  1996cited by this paper
• Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.

  1996cited by this paper
• Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).

  1996cited by this paper
• Role of VEGF-flt receptor system in normal and tumor angiogenesis.

  1995cited by this paper
• Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.

  1987cited by this paper
• Surface Marker for the Lineage of Monocyte-macrophages in Humans Flt-1, Vascular Endothelial Growth Factor Receptor 1, Is a Novel Cell

  year unknowncited by this paper

• VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions

  2020cites this paper
• Translational models of prostate cancer bone metastasis

  2018cites this paper
• Light‐enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune‐mediated efficacy

  2018cites this paper
• Irradiated VEGF164-modified tumor cell vaccine protected mice from the parental tumor challenge

  2017cites this paper
• Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein

  2017cites this paper
• Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside

  2016cites this paper
• Transition State Structure of RNA Depurination by Saporin L3.

  2016cites this paper
• Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.

  2014cites this paper
• VEGF-A promotes IL-17A-producing γδ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells.

  2014cites this paper
• Design , Synthesis and Evaluation of 1 , 3 , 2 Diazaphosphorin [ 4 , 5b ] Quinoxaline-5 , 10-diN-oxide Derivatives as Novel VEGFR-2 and SRC Kinase Inhibitors in the Treatment of Prostate Cancer

  2013cites this paper
• Design, Synthesis and Evaluation of 1,3,2 Diazaphosphorin[4,5-b]Quinoxaline-5,10-di-N-oxide Derivatives as Novel VEGFR-2 and SRCKinase Inhibitors in the Treatment of Prostate Cancer

  2013cites this paper
• Large Molecule Therapeutics The Functionalized Human Serine Protease Granzyme B / VEGF 121 Targets Tumor Vasculature and Ablates Tumor Growth

  2013cites this paper
• The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth

  2013cites this paper
• Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.

  2012cites this paper
• Inhibition of Prostate Cancer Osteoblastic Progression with VEGF121/rGel, a Single Agent Targeting Osteoblasts, Osteoclasts, and Tumor Neovasculature

  2011influential citation
• Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis.

  2011cites this paper
• Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2

  2011cites this paper
• Doubles inhibiteurs de met et vegf pour le traitement du cancer de la prostate résistant à la castration et des métastases osseuses ostéoblastiques

  2011cites this paper
• Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

  2010cites this paper
• Tumor-bone cell interactions in bone metastases

  2010cites this paper
• Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.

  2010cites this paper
• Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature.

  2009cites this paper
• Recent progress in research on ribosome inactivating proteins.

  2009cites this paper
• Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.

  2009cites this paper
• Angiogenesis and Bone Metastasis: Implications for Diagnosis, Prevention and Treatment

  2009cites this paper
• Chapter 64 – Localized Osteolysis

  2008cites this paper
• VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin.

  2008cites this paper
• Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

  2008cites this paper
• A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays.

  2008cites this paper
• Generierung und Charakterisierung von spezifischen T-Zell-Antworten gegen Pilz- und Tumorantigene

  2008cites this paper
• New approaches in tumour immunology: Implications from mass spectrometric analyses of HLA-ligands

  2008cites this paper
• Differential expression of capillary VEGF isoforms following traumatic brain injury

  2007cites this paper
• Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.

  2007cites this paper
• Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial

  2007cites this paper